Atezolizumab as a Second-Line Treatment for Non-Small Cell Lung Cancer
Keywords:
Atezolizumab, Carcinoma de pulmón no células pequeñas, InmunoterapiaAbstract
Introduction: Atezolizumab is indicated as a second-line treatment for locally advanced or metastatic non-small cell lung cancer.
Objective: To evaluate the efficacy of atezolizumab in patients with advanced non-small cell lung cancer after progression to platinum salt treatment.
Methods: A descriptive and retrospective study was conducted in a population of patients with advanced non-small cell lung cancer, treated with atezolizumab after progression with at least one prior line of platinum salt chemotherapy at Hermanos Ameijeiras Hospital in the 2018- 2021period.
Results: Thirty-one patients were included with a mean follow-up of 13.6 months. The median age was 57 years, there was a slight female predominance (51.6%) at the time of starting treatment with atezolizumab, and more than half of the subjects had distant metastases (61.3%). All patients received at least one dose of atezolizumab, with a median of six treatment cycles (range 1-36). The median progression-free survival was 2.9 months (CI, 0.83-4.9) and the median overall survival was 12.5 (CI, 0.1-30.7) with survival rates of 64% and 50% at 6 and 12 months, respectively. Only 2 patients (6.45%) had grade 3 adverse events that led to treatment discontinuation.
Conclusions: Atezolizumab was well tolerated and showed benefits in terms of overall survival, similar to what other authors have reported in the treatment of patients with advanced non-small cell lung cancer.
Keywords: atezolizumab; non-small cell lung cancer; survival.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Haslen Hassiul Cáceres Lavernia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
